Eltrombopag

Active ingredient: Eltrombopag Olamine

In short: Eltrombopag tablets are indicated for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag tablets should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the

Forms & strengthsTablets 12.5 mg tablets — white, round, film-coated tablets, imprinted with A104 on one side and plain on the other side. Each tablet, for oral administration, contains eltrombopag olamine, equivalent to 12.5 mg of eltrombopag free acid. …
LabelTeva Pharmaceuticals, Inc.
Label updatedSep 21, 2026

What is Eltrombopag used for?

Eltrombopag tablets are indicated for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag tablets should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy.

Eltrombopag tablets are indicated in combination with standard immunosuppressive therapy (IST) for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.

Eltrombopag tablets are indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Eltrombopag tablets are not indicated for the treatment of patients with myelodysplastic syndromes (MDS) .

Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection.

âš  Boxed warning (FDA's strongest warning)

In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation .

Eltrombopag may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended .

Eltrombopag dosage

Use the lowest dose of eltrombopag tablets to achieve and maintain a platelet count necessary to initiate and maintain antiviral therapy with pegylated interferon and ribavirin. Dose adjustments are based upon the platelet count response. Do not use eltrombopag tablets to normalize platelet counts . In clinical trials, platelet counts generally began to rise within the first week of treatment with eltrombopag tablets .

Initial Dose Regimen: Initiate eltrombopag tablets at a dose of 25 mg orally once daily.

Monitoring and Dose Adjustment: Adjust the dose of eltrombopag tablets in 25 mg increments every 2 weeks as necessary to achieve the target platelet count required to initiate antiviral therapy. Monitor platelet counts every week prior to starting antiviral therapy.

During antiviral therapy, adjust the dose of eltrombopag tablets to avoid dose reductions of peginterferon. Monitor CBCs with differentials, including platelet counts, weekly during antiviral therapy until a stable platelet count is achieved. Monitor platelet counts monthly thereafter. Do not exceed a dose of 100 mg daily. Monitor clinical hematology and liver tests (e.g., transaminases and bilirubin) regularly throughout therapy with eltrombopag tablets .

For specific dosage instructions for peginterferon or ribavirin, refer to their respective prescribing information.

Platelet count result | Dose adjustment or response

< 50 x 109/L following at least 2 weeks of eltrombopag tablets | Increase daily dose by 25 mg to a maximum of 100 mg/day.

≥ 200 x 109/L to ≤ 400 x 109/L at any time | Decrease the daily dose by 25 mg.

Wait 2 weeks to assess the effects of this and any subsequent dose adjustments.

> 400 x 109/L | Stop eltrombopag tablets; increase the frequency of platelet monitoring to twice weekly.

Once the platelet count is < 150 x 109/L, reinitiate therapy at a daily dose reduced by 25 mg.

For patients taking 25 mg once daily, reinitiate therapy at a daily dose of 12.5 mg.

> 400 x 109/L after 2 weeks of therapy at lowest dose of eltrombopag tablets | Discontinue eltrombopag tablets.

Discontinuation: The prescribing information for pegylated interferon and ribavirin include recommendations for antiviral treatment discontinuation for treatment futility. Refer to pegylated interferon and ribavirin prescribing information for discontinuation recommendations for antiviral treatment futility.

Eltrombopag tablets should be discontinued when antiviral therapy is discontinued. Excessive platelet count responses, as outlined in Table 2, or important liver test abnormalities also necessitate discontinuation of eltrombopag tablets .

First-Line Severe Aplastic Anemia

Initiate eltrombopag tablets concurrently with standard immunosuppressive therapy . …

How to take Eltrombopag — instructions & advice from the label

Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide).

Prior to treatment, patients should fully understand and be informed of the following risks and considerations for eltrombopag tablets:

Risks

Hepatotoxicity

Therapy with eltrombopag tablets may be associated with hepatobiliary laboratory abnormalities .

Advise patients with chronic hepatitis C and cirrhosis that they may be at risk for hepatic decompensation when receiving eltrombopag tablets with alfa interferon therapy .

Advise patients that they should report any of the following signs and symptoms of liver problems to their healthcare provider right away .

yellowing of the skin or the whites of the eyes (jaundice)

unusual darkening of the urine

unusual tiredness

right upper stomach area pain

confusion

swelling of the stomach area (abdomen)

Risk of Bleeding Upon Eltrombopag Tablets Discontinuation

Advise patients that thrombocytopenia and risk of bleeding may reoccur upon discontinuing eltrombopag tablets, particularly if eltrombopag tablets are discontinued while the patient is on anticoagulants or antiplatelet agents. …

Warnings & precautions

Do not take this medicine if: None.

In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation. In two controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, ascites and encephalopathy occurred more frequently on the arm receiving treatment with eltrombopag plus antivirals (7%) than the placebo plus antivirals arm (4%). Patients with low albumin levels (less than 3.5 g/dL) or Model for End-Stage Liver Disease (MELD) score greater than or equal to 10 at baseline had a greater risk for hepatic decompensation on the arm receiving treatment with eltrombopag plus antivirals. Discontinue eltrombopag if antiviral therapy is discontinued.

Eltrombopag may increase the risk of severe and potentially life-threatening hepatotoxicity . Eleven patients (1%) with chronic hepatitis C treated with eltrombopag in clinical trials experienced drug-induced liver injury.

Treatment of Chronic Hepatitis C-associated Thrombocytopenia, and Refractory Severe Aplastic Anemia

Measure serum ALT, AST, and bilirubin prior to initiation of eltrombopag, every 2 weeks during the dose adjustment phase, and monthly following establishment of a stable dose . Eltrombopag inhibits UDP- glucuronosyltransferase (UGT)1A1 and organic anion-transporting polypeptide (OATP)1B1, which may lead to indirect hyperbilirubinemia. If bilirubin is elevated, perform fractionation. Evaluate abnormal serum liver tests with repeat testing within 3 to 5 days. If the abnormalities are confirmed, monitor serum liver tests weekly until resolved or stabilized. …

Eltrombopag side effects

The following clinically significant adverse reactions associated with eltrombopag are described in other sections.

Hepatic Decompensation in Patients with Chronic Hepatitis C

Hepatotoxicity

Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia

Thrombotic/Thromboembolic Complications

Cataracts

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Chronic Hepatitis C-associated Thrombocytopenia: In the two placebo-controlled trials, 955 patients with chronic hepatitis C-associated thrombocytopenia received eltrombopag. Table 11 presents the most common adverse drug reactions (experienced by greater than or equal to 10% of patients receiving eltrombopag compared with placebo).

Adverse reaction | Eltrombopag

+ Peginterferon/Ribavirin

n = 955

(%) | Placebo

+ Peginterferon/Ribavirin

n = 484

(%)

Anemia | 40 | 35

Pyrexia | 30 | 24

Fatigue | 28 | 23

Headache | 21 | 20

Nausea | 19 | 14

Diarrhea | 19 | 11

Decreased appetite | 18 | 14

Influenza-like illness | 18 | 16

Insomniaa | 16 | 15

Asthenia | 16 | 13

Cough | 15 | 12

Pruritus | 15 | 13

Chills | 14 | 9

Myalgia | 12 | 10

Alopecia | 10 | 6

Peripheral edema | 10 | 5

aIncludes PTs of insomnia, initial insomnia, and poor quality sleep. …

Drug interactions

Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids.

Take eltrombopag at least 2 hours before or 4 hours after any medications or products containing polyvalent cations, such as antacids, dairy products, and mineral supplements to avoid significant reduction in absorption of eltrombopag due to chelation .

Use caution when concomitantly administering eltrombopag and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). Monitor patients closely for signs and symptoms of excessive exposure to the drugs that are substrates of OATP1B1 or BCRP and consider reduction of the dose of these drugs, if appropriate. In clinical trials with eltrombopag, a dose reduction of rosuvastatin by 50% was recommended.

HIV Protease Inhibitors: No dose adjustment is recommended when eltrombopag is coadministered with lopinavir/ritonavir (LPV/RTV). …

About this medicine

Eltrombopag tablets contain eltrombopag olamine, a small molecule thrombopoietin (TPO) receptor agonist for oral administration.

Eltrombopag olamine is a biphenyl hydrazone. The chemical name for eltrombopag olamine is 3'-{(2Z)-2-[1- (3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3- biphenylcarboxylic acid - 2-aminoethanol (1:2). It has the molecular formula C25H22N4O4 • 2(C2H7NO). The molecular weight is 564.65 g/mol for eltrombopag olamine and 442.5 g/mol for eltrombopag free acid. Eltrombopag olamine has the following structural formula:

Eltrombopag olamine is practically insoluble in aqueous buffer across a pH range of 1 to 7.4, and is sparingly soluble in water.

Eltrombopag tablets contain eltrombopag olamine in the amount equivalent to 12.5 mg, 25 mg, or 75 mg of eltrombopag free acid. The inactive ingredients of eltrombopag tablets are: Tablet Core: colloidal silicon dioxide, magnesium stearate, mannitol, microcrystalline cellulose, povidone K-30, and sodium starch glycolate type B (potato). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 42ad8f58-bd6c-4f0e-9017-f2da2893fcae. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin